Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1 Interventional

Cisplatin + RT for Triple Negative Breast Cancer

ClinicalTrials.gov ID: NCT01674842

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT01674842. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 12:09 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I Dose-Escalation Study of Cisplatin and Radiation Therapy for Patients With Triple Negative Breast Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase I dose escalation study of cisplatin and concurrent radiation in patients with ER negative, PR negative and HER2 negative breast cancer who have undergone breast-conserving surgery or mastectomy. Primary objective: To assess the safety, tolerability, and maximum tolerated dose (MTD) of cisplatin when given concurrently with radiation therapy for participants with Stage II or III breast cancer who have undergone breast conserving surgery or mastectomy

Study identification

NCT ID
NCT01674842
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Enrollment
55 participants

Conditions and interventions

Conditions

Interventions

Radiation · Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 2012 (Type not available)
Primary completion
Aug 2018 (Actual)
Completion
Jun 8, 2021 (Actual)
Last update posted
Aug 25, 2021

2012 – 2021

United States locations

U.S. sites
5
U.S. states
1
U.S. cities
3
Facility City State ZIP Site status
Massachusetts General Hospital Boston Massachusetts 02114 —
Brigham and Women's Hospital Boston Massachusetts 02115 —
Dana-Farber Cancer Institute Boston Massachusetts 02115 —
Dana-Farber at Milford Milford Massachusetts 01757 —
Dana Farber at South Shore Hospital Weymouth Massachusetts 02190 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01674842, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 25, 2021 · Synced Nov 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.